Biohaven Pharmaceutical (NYSE: BHVN) is one of 188 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Biohaven Pharmaceutical to related businesses based on the strength of its valuation, profitability, earnings, dividends, risk, analyst recommendations and institutional ownership.
Institutional & Insider Ownership
47.8% of Biohaven Pharmaceutical shares are held by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 14.5% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Biohaven Pharmaceutical and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Biohaven Pharmaceutical||N/A||-$63.67 million||N/A|
|Biohaven Pharmaceutical Competitors||$217.40 million||-$39.57 million||-60.78|
Biohaven Pharmaceutical’s rivals have higher revenue and earnings than Biohaven Pharmaceutical.
This is a summary of current recommendations and price targets for Biohaven Pharmaceutical and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Biohaven Pharmaceutical Competitors||560||2524||6776||133||2.65|
Biohaven Pharmaceutical presently has a consensus price target of $38.00, indicating a potential upside of 33.71%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.72%. Given Biohaven Pharmaceutical’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Biohaven Pharmaceutical is more favorable than its rivals.
This table compares Biohaven Pharmaceutical and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Biohaven Pharmaceutical Competitors||-4,612.92%||-471.96%||-42.70%|
Biohaven Pharmaceutical beats its rivals on 6 of the 11 factors compared.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.